TABLE 2.
Scenario inputs, 2017‐2031
| Status quo | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2025+ |
|---|---|---|---|---|---|---|---|
| Treated | 45 000 | 56 400 | 44 600 | 33 700 | 23 200 | 15 100 | 15 100 |
| Newly diagnosed/newly linked to care | 30 400 | 30 400 | 20 ,000 | 20 000 | 20 000 | 20 000 | 20 000 |
| Fibrosis score restriction | ≥F0 | ≥F0 | ≥F0 | ≥F0 | ≥F0 | ≥F0 | ≥F0 |
| New infections | 8200 | 7500 | 6700 | 6100 | 5600 | 5200 | 5200 |
| Treated ages | 15+ | 15+ | 15+ | 15+ | 15+ | 15+ | 15+ |
| SVR | 95% | 95% | 98% | 98% | 98% | 98% | 98% |
| GHSS elimination | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2025+ |
|---|---|---|---|---|---|---|---|
| Treated | 45 000 | 56 400 | 44 600 | 35 700 | 35 700 | 36 700 | 38 000 |
| Incremental newly diagnosed/newly linked to care | — | — | 10 400 | 13 400 | 13 400 | 15 400 | 16 400 |
| Fibrosis score restriction | ≥F0 | ≥F0 | ≥F0 | ≥F0 | ≥F0 | ≥F0 | ≥F0 |
| New infections | 8200 | 7500 | 6700 | 5500 | 5000 | 4100 | 2600 |
| Treated ages | 15+ | 15+ | 15+ | 15+ | 15+ | 15+ | 15+ |
| SVR | 95% | 95% | 98% | 98% | 98% | 98% | 98% |
Abbreviations: GHSS, Global Health Sector Strategy; SVR, sustained virologic response.